Efficacy of Caregiver Training Program in Enhancing Caregiver and Patient Outcomes
1 other identifier
interventional
50
1 country
1
Brief Summary
As part of Phase II of the NIH SBIR grant, the study will conduct a randomized controlled clinical trial in which the MapHabit system (MHS) will offer a caregiver training product that is linked to MHS, an Alzheimer's disease or related dementias (AD/ADRD) assistive technology product that uses visual maps to improve a patient's behavior and sense of autonomy. MapHabit's combined areas of focus, i.e., offer a single integrated product to address the caregiver and the person under this caregiver's care, are unique and will create a new standard in the field to reduce caregiver burden in the setting of caring for individuals with AD/ADRD. Additionally, the study will integrate enhanced user support modules, i.e., gamifying, dashboarding, and social networking, to improve the Caregiver Training Program (CTP) experience.The study will be a randomized controlled clinical trial, in which two conditions will be investigated: 1) control condition in which the MHS alone is incorporated in the participant's daily care and 2) experimental condition in which the MHS+CTP is implemented into the daily care received by participants. The sample size will be a total of 50 patient-caregiver dyads, 25 in each condition. The study duration will be a 6-month intervention.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable alzheimer-disease
Started Aug 2024
Shorter than P25 for not_applicable alzheimer-disease
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 31, 2022
CompletedFirst Posted
Study publicly available on registry
September 2, 2022
CompletedStudy Start
First participant enrolled
August 24, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2025
CompletedOctober 2, 2025
September 1, 2025
1.3 years
August 31, 2022
September 28, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (6)
Change in User Interaction and Engagement from baseline at 6 months
18-item quality-of-life questionnaire (QoL-18) evaluates a range of participants' behaviors, including mood, engagement, and memory at the end of the study compared to before the use of the MHS. The instrument is scored on a Likert Scale, ranging from 1-10. A higher number indicates better outcome.
Pre-Post: The instrument will be administered to the participants at baseline, post-intervention (6 months)
Change in Zarit Burden Assessment Caregiver Strain instrument from baseline at 6 months
18-item questionnaire assessing the various stresses caregivers experienced relating to caring for an individual with cognitive impairment. The total score ranges from 0-72, with a higher score reflecting higher stress and burden on the caregiver.
Pre-Post: The instrument will be administered to the participants at baseline, post-intervention (6 months)
Change in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) from baseline at 6 months
Assesses an individual with dementia's ability to carry out activities of daily living. The total score ranges from 0-53, with a higher score representing better performance in completing activities of daily living by the individual with dementia.
Pre-Post: The instrument will be administered to the participants at baseline, post-intervention (6 months)
Change in Quality of Life - 18 (QoL-18) from baseline at 6 months
18-item quality-of-life questionnaire (QoL-18) evaluated a range of participants' behaviors, including mood, engagement, and memory at the middle and end of the study compared to before the use of the MHS. The instrument is scored on a Likert Scale, ranging from 1-10. A higher number indicates better outcome.
Pre-Post: The instrument will be administered to the participants at baseline, post-intervention (6 months)
Change in Brief Quality of Life - 8 (QoL-8) from baseline at 6 months
8-items selected from the Wisconsin Quality of Life Caregiver Questionnaire evaluated a range of participants' behaviors, including mood, engagement, and memory at the middle and end of the study compared to before the use of the MHS. The instrument is scored on a Likert Scale, ranging from 1-10. A higher number indicates better outcome.
Pre-Post: The instrument will be administered to the participants at baseline, post-intervention (6 months)
Change in Caregiver Self-Assessment Questionnaire from baseline at 6 months
12-item, caregiver self-report measure of stress levels
Pre-Post: The instrument will be administered to the participants at baseline, post-intervention (6 months)
Secondary Outcomes (4)
2-item Satisfaction Scale (SS-2)
The instrument was administered to the participants after the completion of the study duration (i.e., assessed at 6 months)
Pain and Sleep Questionnaire
Pre-Post: The assessment will be administered at baseline, post-intervention (6 months)
Generalized Anxiety Disorder (GAD7) Scale
Pre-Post: The assessment will be administered at baseline, post-intervention (6 months)
Anger Management Scale
Pre-Post: The assessment will be administered at baseline, post-intervention (6 months)
Study Arms (2)
Caregiver Training Program
EXPERIMENTALThis condition will involve the implementation of an assistive technology software (named the MapHabit System) with an added Caregiver Training Program into the daily care of individuals with mild to moderate stages of Alzheimer's disease and related dementias. The MapHabit System (MHS) is a commercially available visual mapping software application that utilizes visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The application will be made available to families through compatible tablets.
The MapHabit System
ACTIVE COMPARATORThis control condition will act as the active comparator to the experimental condition. The same assistive technology, the MapHabit System, will be given to a separate group of participants. The difference here will be that the software will be a version that does not include the caregiver training program.
Interventions
The MapHabit System (MHS) is a commercially available visual mapping software application that utilizes visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application will be made available through tablets. Depending on the condition, participants will receive a specific version of the application. The experimental condition will receive the version that incorporates gamified structure and the Caregiver Training Program. The MHS is a general wellness product. This functionality is not a regulated medical device.
Eligibility Criteria
You may qualify if:
- Individual diagnosed with Alzheimer's disease or other related dementia (ADRD) in their mild to moderate stage of impairment
- Participating caregiver of individual with dementia must be the primary caregiver
- Proficient in English
You may not qualify if:
- Individual not diagnosed with ADRD
- Participating caregiver of individual with dementia is NOT the primary caregiver
- Not proficient in English
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- MapHabit, Inc.lead
Study Sites (1)
MapHabit, Inc.
Atlanta, Georgia, 30308, United States
Related Publications (3)
Boatman F, Golden M, Jin J, Kim Y, Law S, Lu A, Merriam N, Zola S. Assistive technology: Visual mapping combined with mobile software can enhance quality of life and ability to carry out activities of daily living in individuals with impaired memory. Technol Health Care. 2020;28(2):121-128. doi: 10.3233/THC-191980.
PMID: 31796718BACKGROUNDKelleher J, Zola S, Cui X, Chen S, Gerber C, Parker MW, Davis C, Law S, Golden M, Vaughan CP. Personalized Visual Mapping Assistive Technology to Improve Functional Ability in Persons With Dementia: Feasibility Cohort Study. JMIR Aging. 2021 Oct 19;4(4):e28165. doi: 10.2196/28165.
PMID: 34269690BACKGROUNDParker MW, Davis C, White K, Johnson D, Golden M, Zola S. Reduced care burden and improved quality of life in African American family caregivers: Positive impact of personalized assistive technology. Technol Health Care. 2022;30(2):379-387. doi: 10.3233/THC-213049.
PMID: 34334439BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Stuart Zola
MapHabit, Inc.
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Masking Details
- Statistical analyses of all data will be carried out independently of investigators by a biostatistical resource department of an academic health center for validation.
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chief Scientific Officer
Study Record Dates
First Submitted
August 31, 2022
First Posted
September 2, 2022
Study Start
August 24, 2024
Primary Completion
November 30, 2025
Study Completion
December 31, 2025
Last Updated
October 2, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
- Time Frame
- Immediately following publication. No end date.
- Access Criteria
- Researchers who provide a methodologically sound proposal. Proposals should be directed to szola@maphabit.com. To gain access, data requestors will need to sign a data access agreement.
All of the individual participant data collected during the trial, after deidentification.